Search Results for “EC” – Page 100 – media

New Orleans infection preventionists adapt adult protocols to reduce infections in babies

Facing persistent cases of hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) during the pandemic, the infection prevention and control (IPC) team at Children’s Hospital New Orleans developed an inexpensive nasal decolonization regimen previously used only in their adult patients that decreased rates of MRSA by 50 percent. Their results are being presented at the Association for Professionals in Infection Control and Epidemiology’s (APIC’s) Annual Conference in Orlando Florida, June 26-28. Without a lot of scientific literature on nasal decolonization in the pediatric population to guide them, Infection Preventionist Jennifer Schroeder, MPH, CIC, and colleagues designed two nasal decolonization protocols to fit their patient population—one for children younger than two, and the other for children older than two. The intervention took place in the hospital’s critical care units because most of the MRSA was occurring there. The team swabbed the nostrils of patients admitted to their cardiac intensive care unit, neonatal intensive care ...
- Source: drugdu
- 102
- June 27, 2023
Initiative helps neurosurgical infections drop more than 80% in two years at Pittsburgh hospital

When excess surgical site infections (SSIs) were detected among neurosurgery patients at University of Pittsburgh Medical Center (UPMC) Mercy in 2019, infection preventionist Katie Palladino, MPH, CPH, CIC, partnered with a hospital neurosurgeon on a multidisciplinary quality and process improvement initiative that led to a steep drop in infection rates over a two-year period. Their successful initiative is being presented at the Association for Professionals in Infection Control and Epidemiology’s (APIC’s) Annual Conference in Orlando Florida, June 26-28. Palladino and the surgeon began the initiative by reviewing the path of a surgical patient—from the first pre-op meeting to the surgery, to the patient’s discharge from the hospital—observing practices and looking for opportunities where infections could arise. They also reviewed pre-surgical instructions for patients and found ways to improve information about chlorhexidine gluconate (CHG) bathing, nasal decolonization, and other important infection prevention practices. The next step was a literature review of ...
- Source: drugdu
- 107
- June 27, 2023
Biotech AltPep scores around $53m in Series B funding round

US-based amyloid diseases treatment solutions developer AltPep has raised $52.9m in its Series B investment round led by Senator Investment Group. Former investors such as Matrix Capital Management Company and Alexandria Venture Investments, who took part in the firm’s Series A round, joined the latest fundraise along with new backers. The new investors in Series B include Eli Lilly and Company, Partners Investment, and Section 32. As part of the deal, Senator Investment Group’s Rohit Vanjani will join the AltPep board. Besides, Lilly’s senior vice president and chief scientific officer for Neurobiologicals Ronald DeMattos will become a member of the Scientific Advisory Board at AltPep. Vanjani noted: “We believe AltPep is in an excellent position to optimise the value of its unique technology. “With scientific application for both therapeutics and diagnostics in a wide range of amyloid diseases, the potential for the company’s pipeline is vast and extremely promising.” The ...
- Source: drugdu
- 207
- June 27, 2023
Intercept restructures as Ocaliva’s NASH hopes dashed again with FDA rejection

Even after a second application attempt, Intercept’s Ocaliva wasn’t the fatty liver disease breakthrough that the company had hoped it would be. Three years after an initial rejection, the FDA once again turned down Ocaliva, or obeticholic acid, for nonalcoholic steatohepatitis (NASH) patients with stage 2 or 3 liver fibrosis, Intercept said Thursday. The denial means patients with NASH will have to wait longer for the first FDA-approved therapy and that a market estimated to be worth multiple billions of dollars still awaits a winner. For Intercept, it also means it’s time for a new direction. Intercept has decided to discontinue all NASH-related investment and restructure its operations, with the goal to save about $140 million in operating costs, the company said Friday. Measures it’s taking include winding down a long-term patient outcomes follow-up of the phase 3 REGENERATE study for Ocaliva in NASH. All R&D, commercial, medical affairs and ...
- Source: drugdu
- 105
- June 27, 2023
Study explores the use of deep learning algorithm to detect occlusal caries

A diagnostic study on the detection of occlusal caries from a clinical photograph using a deep learning algorithm will be presented at the 101st General Session of the IADR, which will be held in conjunction with the 9th Meeting of the Latin American Region and the 12th World Congress on Preventive Dentistry on June 21-24, 2023, in Bogotá, Colombia. The Interactive Talk presentation, “Automated Detection of Occlusal Caries Using Deep Learning Algorithm,” will take place on Saturday, June 24 at 4:25 p.m. Colombia Time (UTC-05:00) during the “Prevalence of Health Conditions and Risk Factors” session. The study by Chukwuebuka Elozona Ogwo of Temple University, Philadelphia, PA, U.S. sought to determine the accuracy, precision, and sensitivity of the YOLOv7 object detection algorithm in occlusal caries detection from clinical photographs and (2) develop software for occlusal caries detection. Only consenting adults (>=18 years old) with permanent dentition receiving care at the Temple ...
- Source: drugdu
- 99
- June 26, 2023
analysts

Dive Brief Intuitive Surgical’s minimally invasive bronchoscopy platform Ion may provide “some of the most exciting advancements in robotic technology” in the coming years, according to analysts at BTIG. While Ion contributed an estimated $115 million of the company’s $6.2 billion in revenue last year, the analysts see scope for Intuitive to grow sales by capturing more of the lung biopsy market and expanding into the ablation of tumors. Intuitive competes for the bronchoscopy market with Johnson & Johnson’s Monarch platform. The analysts estimate there are about twice as many Ion systems as Monarch devices in use. Dive Insight Intuitive’s success rests on its da Vinci robotic platform and discussions of the future of the company focus on whether J&J and Medtronic can challenge the dominance of that device, the BTIG analysts said. “Intuitive’s push into robotic bronchoscopy is purposeful, not just simply for the bronchoscopy opportunity, but for its ...
- Source: drugdu
- 102
- June 26, 2023
Empress Therapeutics emerges with $50m to fund small molecule development

Life sciences venture capital firm Flagship Pioneering has unveiled Empress Therapeutics, a small molecule drug development startup. The Moderna-backed venture fund has launched Empress with a $50m investment. This will support development of its proprietary Chemilogics platform and drug discovery pipeline. So far, Empress claims to have generated 15 drug leads across multiple indications. These span multiple structural classes and target several classes of proteins, including cytokines, enzymes, G protein-coupled receptors (GPCRs), and ion channels. With this pipeline, Empress hopes to address unmet clinical needs in immune and inflammatory conditions, and metabolic, neurologic, oncologic, and pain disorders. The company expects to file multiple IND applications in these areas over the next couple of years. Empress benefits from a wealth of clinical data, and recent advances in genomics, artificial intelligence (AI) and synthetic biology. This allows the company’s platform to read genetic code and use biosynthetic instructions to find, make and ...
- Source: drugdu
- 116
- June 23, 2023
Research reveals a potential gap in recommended care for people with obesity and overweight

By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. “The number of people with obesity is high and rising in the adult U.S. population. Obesity is a complex and expensive disease that has been implicated in many chronic conditions including high blood pressure, diabetes, and cardiovascular diseases,” said Kyrian Ezendu, Ph.D., an Eli Lilly and Company advisor on benefit-risk research. “Medications to treat obesity are an integral part of long-term care for people with excess weight and are recommended for people with obesity or people with overweight and at least one obesity-related condition.” Ezendu and colleagues used data from linked electronic health records and insurance claims of people ages 18 to 80 years ...
- Source: drugdu
- 249
- June 20, 2023
Radioactive iodine or surgery linked to decreased mortality risk in patients with hyperthyroidism

Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago. Kristien Boelaert (M.D., Ph.D., Professor of Endocrinology, University of Birmingham, United Kingdom) said, “Hyperthyroidism or an overactive thyroid gland is common, affecting up to 3% of the population, and is associated with long-term adverse cardiac and metabolic consequences. The optimal treatment choice remains unclear.” Boelaert and colleagues identified 55,318 patients with newly diagnosed hyperthyroidism, treated with antithyroid drugs (ATD; 77.6%), radioiodine (14.6%), or thyroidectomy (7.8%) from a U.K. population-based electronic health record database for the EGRET Study. They examined all-cause mortality, major cardiovascular events (MACE: cardiovascular death, heart failure, or stroke), and post-treatment obesity. The average follow-up was roughly 12 years. Those treated with antithyroid drugs had an estimated mean survival of 12 years, according to the data. Survival ...
- Source: drugdu
- 110
- June 20, 2023
ANeuroTech shares plans for major depressive disorder pivotal programme

Belgium-headquartered ANeuroTech is participating in a Series B round, which will raise up to $150m to power the pivotal programme of its lead candidate ANT01 for use as an adjunctive treatment for major depressive disorder (MDD). This includes the company’s upcoming Phase IIIb trial, but also another Phase III study and a long-term safety trial, said ANeuroTech CEO Eric Buntinx in an interview with Pharmaceutical Technology. The company has already contacted funds based in Europe and in the US, said Buntinx. He added that ANeuroTech is speaking to more than ten different parties. The company plans to finish the round by September or October at the latest. ANeuroTech previously raised an undisclosed amount of capital as part of a Series A round, which featured investment from impact finance firm KOIS. ANT01 consists of a 15mg dose of pipamperone, which is a serotonin-2A and dopamine-4 blocker, per the company’s website. While ...
- Source: drugdu
- 115
- June 20, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.